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Hypoxia in Alzheimer’s disease: 
effects of hypoxia inducible factors
A l z h e i m e r ’s  d i s e a s e  ( A D ) ,  a  c o m m o n 
neurodegenerative disease, afflicts 26 million 
people worldwide currently with projection of a 
fourfold increase in this figure by the year 2050 
(Brookmeyer et al., 2018). The majority of AD 
cases (95%) are sporadic, having the late-onset 
affecting those over 65 years old. About 15% 
among those 65 years and older suffer from 
AD, and the incidence of AD is close to 50% for 
those aged over 85 years (Brookmeyer et al., 
2018). There are a number of changes in the 
ageing brain, such as reduced cerebral blood 
flow, white matter changes, iron overload, 
and neuroinflammation (Chen et al., 2010). 
The reduction of cerebral blood flow leads to 
hypoperfusion, thus causing cerebral hypoxia, 
which is a common vascular component among 
the AD risk factors. Prolonged and severe 
hypoxia can cause neuronal loss and memory 
impairment. It has been understood that 
patients with stroke are at risk of AD. Up to 
1/3 of stroke survivors suffer from post stroke 
dementia (Mijajlovic et al., 2017). The most 
common cause of post stroke dementia are 
vascular dementia, AD and mixed dementia.
Hypoxia is a condition where oxygen tensions 
are below the normal level of tissue oxygen 
tension (Chen et al., 2018). Hypoxia can be 
classified as acute, intermittent, chronic 
according to the duration; mild, moderate, 
severe according to the extent. The duration 
and extent of hypoxia in different cells dictate 
their beneficial or detrimental effects on the 
cells. Severe and/or chronic hypoxia, impair 
delivery of oxygen, affect cellular metabolism, 
ATP production, Ca2+ homeostasis, and lead to 
reactive oxygen species (ROS) formation and 
inflammation (Chen et al., 2018). While mild, 
moderate and/or intermittent hypoxia have 
been found to induce protective adaptations in 
the brain (Lall et al., 2019).
In the AD process, hypoxia enhances a shift in 
amyloid precursor protein processing toward 
the amyloidogenic pathway and down-regulates 
the function of α-secretase. Hypoxia inhibits the 
expression and activity of an amyloid-degrading 
peptidase ‘neprilysin’ in cortical neurons of rat, 
increasing the accumulation of amyloid beta 
(Aβ) peptides in the affected regions. It has 
been shown that hypoxia interplays with Aβ 
peptide aggravating the neuronal death. There 
is an increase vulnerability of hippocampal 
neurons to Aβ peptide toxicity during hypoxia. 
Calcium dyshomeostasis is a fundamental 
mechanism in AD pathogenesis. Aβ interaction 
with the plasma membrane leads to elevated 
cytoplasmic Ca2+ concentrations and enhances 
excitation of neuron. Chronic hypoxia enhances 
Ca2+ entry and mitochondrial Ca2+ content, 
potentiates posttranscriptional trafficking of 
L-type Ca2+ channels. Both hypoxia and Aβ can 
trigger the activation of microglia, leading to 
a maladaptive neuroinflammatory response. 
Whilst, neuroinflammation itself could be 
another initiating pathological trigger of AD 
(Lall et al., 2019). Neuroinflammation plays 
a detrimental role in AD pathogenesis, as 
microglia depletion by colony stimulating factor 
receptor 1 inhibitors improves AD symptoms in 
in vivo (Rawlinson et al., 2020).
Cells respond to hypoxia by stabilizing hypoxia 
inducible factor (HIF), a key transcription factor 
regulating oxygen homeostasis. The HIF levels 
in cells are directly regulated by four oxygen-
sensitive hydroxylases: 3 prolyl hydroxylases 
(PHD1-3) and 1 asparaginyl hydroxylase, factor 
inhibiting HIF (Chen et al., 2018). Both oxygen 
and 2 oxoglutarate are substrates of these 
enzymes, while iron and ascorbate are co-
factors. In a normal oxygen environment, HIF 
hydroxylase is active and degrades the HIF-α 
subunit. Yet, in a reduced oxygen environment, 
the absence of oxygen as a substrate, renders 
the HIF hydroxylases inactive, thus the HIF-α 
subunit accumulates and binds to the HIF-α 
subunit, forming the HIF molecule (Figure 
1). The stabilization of HIF upregulates the 
expression of hundreds of HIF targeted genes 
that help cells and tissue survival in hypoxia, 
as well as a number of apoptotic genes, such 
as Bax, BNIP3 (Figure 1). HIF-1α is ubiquitously 
expressed, and appears the most active isoform 
during short periods (2–24 hours) of intense 
hypoxia or anoxia (< 0.1% O2) in some cell lines. 
HIF-2α is more tissue specific and is emerging 
as a distinct entity in target gene induction in 
the vascular endothelia cells, and is known as 
an endothelium specific HIF-α isoform. HIF-2α 
is active under mild or physiological hypoxia, 
and continues to be active even after 48–72 
hours of hypoxia. HIF-2α shares 48% amino 
acid homology with HIF-1α, and binds to similar 
promoter sites but differs in the cofactors 
it recruits. HIF-1 and HIF-2 have largely 
overlapping but also some non-redundant 
functions.  In some contexts, HIF-1α  plays a key 
role in initial response to hypoxia whereas HIF-
2α drives the hypoxic response during chronic 
hypoxic exposure.
It has been revealed by sequence analysis and 
gel shift studies that HIF-1 binds to β-secretase 
1 (BACE1) promoter, and that overexpression of 
HIF-1α in neuronal cells increases BACE1 mRNA 
and protein levels, and down-regulation of HIF-
1α reduces the levels of BACE1. It has been 
observed that HIF-1 binds to the promoter of 
anterior pharynx-defective phenotype (APH-
1) to up-regulate its expression, leading to an 
increase in γ-cleavage of amyloid precursor 
protein and Notch. HIF-1 also binds to gene 
promoter of neprilysin and suppresses its 
transcription (Lall et al., 2019).
On the other hand, HIF-1 has been proposed 
as a neuroprotective factor, which has ability to 
suppress neuronal cell death caused by hypoxia 
or oxidative stress, and to protect against Aβ 
peptide toxicity (Zheng et al., 2015; Ashok et 
al., 2017; Merelli et al., 2018). Recombinant 
adeno-associated virus vector expressing 
the human HIF-1α gene recombinant adeno-
Perspective
Halimatu Hassan, Ruoli Chen*
associated virus-HIF-1α inhibits neuronal 
apoptosis of the hippocampus induced by 
Aβ peptides. HIF-1 increases glycolysis and 
the hexose monophosphate shunt, maintains 
the mitochondrial membrane potential and 
cytosolic accumulation of cytochrome C, 
thereby inactivating caspase-9 and caspase-3, 
and thus prevents neuronal death in the AD 
brain. Oxidative damage, caused by Aβ peptide 
induces mitochondrial dysfunction, which is 
a major characteristic of neuronal apoptosis. 
Additional pathological features of AD are 
astrocyte activation and reduced glucose 
metabolism in some selected brain areas. 
Maintenance of HIF-1α levels reverses Aβ 
peptide-induced glial activation and glycolytic 
changes, thus mediating a neuroprotective 
response to Aβ peptide by maintaining 
metabol ic  integr i ty.  HIF-1 is  the major 
transcription factor that increases capillary 
network density and improves blood circulation 
in living tissue by regulating proteins expression 
such as erythropoietin, glucose transporter 
1, 3 and vascular endothelial growth factor. 
Erythropoietin is able to block the Aβ generated 
neuronal apoptosis, while glucose transporter 
1, 3 increase glucose transport into brain nerve 
cells. All in all, HIF-1 participates in hypoxia-
induced adaptive reactions to restore cellular 
homeostasis, and postpone the progression of 
AD (Figure 1).
A group of agents which can upregulate 
the HIF levels in normoxia are termed as 
hypoxia mimetic agents (Chen et al., 2018). 
These  agents  inc lude  H IF  hydroxy lase 
inhibitors and iron chelators. The inhibition 
of HIF hydroxylase not only exerts pleiotropic 
neuroprotective effects as a consequence 
of HIF induction, but also has anti-oxidant 
and anti-inflammatory effects (Figure 1). HIF 
hydroxylase inhibition, which engages multiple 
downstream effector pathways, is a promising 
therapeutic intervention that can challenge the 
heterogeneity in AD pathophysiology present 
in humans. Because the HIF hydroxylase 
inhibition leverages endogenous adaptive 
programs, the breadth of the response will not 
lead to an increased likelihood of toxicity. It is 
important to emphasize that HIF hydroxylase 
inhibition does not equal HIF activation. HIFs 
are only one of a number of growing substrates 
known to modulate via HIF hydroxylase (Chen 
et al., 2018). To our best knowledge, there 
are no studies applying PHD inhibitors for AD 
treatment. Li et al. (2018) applied FG4592 for 
the treatment of Parkinson’s disease both in 
vitro and in vivo. FG4592, a HIF PHD inhibitor, 
is currently used for anaemia treatment in 
patients with chronic kidney disease. Li et 
al. (2018) concluded that FG4592 could be 
potentially used for treating Parkinson’s disease 
by improving the neuronal mitochondrial 
function under oxidative stress. 
Iron chelation has been widely studied to treat 
neurodegenerative diseases, including AD and 
Parkinson’s disease, as iron accumulation is 
common in ageing and in neurodegenerative 
diseases (Devos et al., 2020). Abnormal iron 
metabolism generates hydroxyl  radicals 
through the Fenton reaction, triggers oxidative 
stress reactions, causes lipid peroxidation 
and damages in cell protein and DNA, and 
ultimately leads to cell death. Iron promotes 
Aβ aggregation and induces aggregation of 
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Figure 1｜ Schematic diagram describing effects 
of hypoxia and hypoxia mimetic agents on 
neurons in Alzheimer’s disease (AD) process. 
Severe and/or chronic hypoxia can leads to 
amyloid beta (Aβ) peptide formation and 
aggregation, Ca2+ dyshomeostasis, reactive oxygen 
species (ROS) formation in neurons as well as 
neuroinflammation (Chen et al., 2018). While mild, 
moderate and/or intermittent hypoxia have been 
found to induce protective adaptations in the 
brain (Lall et al., 2019). Hypoxia inducible factor 
(HIF), a key mediator of oxygen homeostasis, 
generates numerous pleiotropic protective effects, 
but also participates in Aβ peptide formation 
and aggregation. Hypoxia mimetic agents, 
both iron chelators and HIF prolyl hydroxylase 
(PHD) inhibitors, can remove ROS and reduce 
neuroinflammation, in addition to activating 
HIF. Pharmacological stabilization of HIF can be 
neuroprotective and be explored as an adjunctive 
therapy for AD.
hyperphosphorylated tau. Iron-Aβ interaction 
exhibits toxic effects through ROS. Iron 
chelators, such as desferoxamine, deferiprone, 
deferasirox, have generated some promising 
results in both preclinical studies and some 
clinical trials for the AD treatment. However, 
the potential role of HIF stabilization by these 
agents has not been documented (Merelli 
et al., 2018). Iron chelators can cause iron 
chelation and HIF activation simultaneously, as 
iron is one of the cofactors of HIF PHD (Figure 
1). M30, a multi-target iron chelator, has been 
reported to increase the HIF-1 protein level 
and to upregulate expression of the HIF-1 
downstream genes, such as vascular endothelial 
growth factor and erythropoietin. It has been 
reported M30 simultaneously attenuates tau 
phosphorylation and protects cortical neurons 
against Aβ25–35 toxicity (Merelli et al., 2018). 
In a series of single blinded clinical trials, 
deferiprone is found to be feasible to treat 
the mild cognitive impairment of AD patients 
(NCT02878538).
However, there was no evidence for the 
cognitive efficacy of two of metal protein 
attenuating compounds – clioquinol and PBT2, 
in AD patients (Sampson et al., 2014). Large 
clinical trials are now requested to demonstrate 
cognitive efficacy of PBT2.
A new generation of iron chelators with 
multifunction is needed for treating AD. 
Ideally, the new agents will have the capacity 
to interfere with another signaling pathway in 
addition to iron chelation, to stop or reverse 
the AD process. Iron chelators can lead to 
both iron chelation and HIF activation, but the 
latter is not well studied when treating the 
neurodegenartive disease with iron chelators. 
Activation of HIF can add an advantage for 
iron chelation therapy to activate endogenous 
neuroregenerative pathways, in addition to 
inhibition of ROS production (Figure 1). Since 
the expression and function of PHDs have been 
shown to vary among tissues, the distinct role 
of HIF alpha isoforms should be considered. 
Attention need to be pay on the ability of 
the novel iron chelators to induce different 
response of HIF-1α and HIF-2α.
In conclusion, cerebral hypoxia is associated 
with AD. The effects of hypoxia on the brain 
depends on its duration and extent. Mild, 
moderate and/or intermittent hypoxia can 
be protective while severe and/or chronic 
hypoxia is detrimental.  Chronic hypoxia 
n o t  o n l y  p ro m o t e s  A β  fo r m a t i o n  a n d 
accumulation, but also aggravates Aβ toxicity 
by increasing ROS and causing calc ium 
dyshomeostasis. Furthermore, both chronic 
hypoxia and Aβ activate microglia leading 
to a neuroinflammatory response, which 
has a detrimental role in AD pathogenesis. 
The restoration of normal oxygen tension 
in the brain would reduce or converse the 
neurodegeneration. The molecules targeted 
by hypoxia can provide therapeutic strategies 
and interventions against some common 
neurodegenerat ive  d iseases ,  inc luding 
the AD. HIF,  an important physiological 
response mechanism to hypoxia, enhances 
neuroprotective compensatory pathways 
involved in many physiological processes. HIF 
stabilization is not the same as hypoxia, and is 
only a part of hypoxia-induced changes in the 
cells.
Pharmacological stabilization of HIF can be 
neuroprotective and explored as an adjunctive 
therapy for AD. Iron chelators have the potential 
to activate HIF in addition to iron chelation. The 
neuroprotective effects of iron chelators are 
acting against the generation of free radicals 
derived from iron, but could also be due to 
upregulation of the hypoxia rescue genes via 
HIF stabilization (Merelli et al., 2018). The 
amount of HIF can be adjusted with doses of 
hypoxia mimetic agents, and the specific HIF-1 
or HIF-2 activation can be achievable (Chen et 
al., 2018). Carefully monitoring the HIF-1 and 
HIF-2 activation by some novel iron chelators 
will help translate iron chelation therapy for 
neurodegenerative diseases, including the AD. 
The tissue specific HIF alpha isoform activation 
by iron chelators merits further investigation.
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